Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor-Based Chemotherapy in Treatment-Naïve AML Patients Unsuitable for Intensive Therapy
NCT07236931Completed
- Start
- Jan 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of selinexor in acute myeloid leukemia (AML). Primary endpoint: Overall Survival at 24 months. Started Jan 2025; status: completed.
02
Drugs
selinexor
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07236931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07236931.